Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) have earned an average rating of “Moderate Buy” from the sixteen ratings firms that are currently covering the company, MarketBeat.com reports. Four investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $74.75.

Several analysts recently issued reports on APLS shares. Wedbush reduced their price target on shares of Apellis Pharmaceuticals from $67.00 to $57.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 17th. HC Wainwright reiterated a “buy” rating and set a $92.00 price target on shares of Apellis Pharmaceuticals in a research report on Tuesday, May 28th. Mizuho reduced their price target on shares of Apellis Pharmaceuticals from $60.00 to $52.00 and set a “neutral” rating on the stock in a research report on Monday, April 29th. Robert W. Baird reiterated an “outperform” rating and set a $100.00 price target on shares of Apellis Pharmaceuticals in a research report on Tuesday, July 23rd. Finally, Piper Sandler assumed coverage on shares of Apellis Pharmaceuticals in a research report on Friday, May 31st. They issued a “neutral” rating and a $46.00 target price on the stock.

Apellis Pharmaceuticals Stock Up 2.2 %

Shares of APLS opened at $39.75 on Wednesday. Apellis Pharmaceuticals has a 12 month low of $19.83 and a 12 month high of $73.80. The firm’s 50 day moving average is $39.58 and its 200-day moving average is $51.70. The stock has a market capitalization of $4.82 billion, a PE ratio of -11.49 and a beta of 0.88. The company has a current ratio of 3.77, a quick ratio of 3.02 and a debt-to-equity ratio of 0.35.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its earnings results on Tuesday, May 7th. The company reported ($0.54) EPS for the quarter, hitting the consensus estimate of ($0.54). The company had revenue of $172.33 million for the quarter, compared to analysts’ expectations of $163.37 million. Apellis Pharmaceuticals had a negative net margin of 79.67% and a negative return on equity of 160.77%. The business’s revenue for the quarter was up 284.3% on a year-over-year basis. During the same period last year, the firm earned ($1.56) earnings per share. Equities research analysts forecast that Apellis Pharmaceuticals will post -1.12 EPS for the current year.

Insider Buying and Selling

In related news, Director A. Sinclair Dunlop sold 37,000 shares of Apellis Pharmaceuticals stock in a transaction on Friday, June 21st. The shares were sold at an average price of $39.24, for a total transaction of $1,451,880.00. Following the completion of the transaction, the director now owns 136,998 shares of the company’s stock, valued at $5,375,801.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Apellis Pharmaceuticals news, insider Pascal Deschatelets sold 78,907 shares of Apellis Pharmaceuticals stock in a transaction on Wednesday, May 8th. The shares were sold at an average price of $42.35, for a total value of $3,341,711.45. Following the completion of the sale, the insider now directly owns 1,115,983 shares of the company’s stock, valued at $47,261,880.05. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director A. Sinclair Dunlop sold 37,000 shares of Apellis Pharmaceuticals stock in a transaction on Friday, June 21st. The shares were sold at an average price of $39.24, for a total transaction of $1,451,880.00. Following the completion of the sale, the director now directly owns 136,998 shares of the company’s stock, valued at $5,375,801.52. The disclosure for this sale can be found here. 6.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Sippican Capital Advisors increased its stake in Apellis Pharmaceuticals by 1.1% in the fourth quarter. Sippican Capital Advisors now owns 16,004 shares of the company’s stock valued at $958,000 after purchasing an additional 170 shares in the last quarter. Simplicity Wealth LLC grew its holdings in shares of Apellis Pharmaceuticals by 0.6% during the second quarter. Simplicity Wealth LLC now owns 78,746 shares of the company’s stock valued at $3,021,000 after buying an additional 499 shares during the last quarter. Future Financial Wealth Managment LLC acquired a new position in shares of Apellis Pharmaceuticals during the first quarter valued at about $29,000. Oppenheimer Asset Management Inc. grew its holdings in shares of Apellis Pharmaceuticals by 8.3% during the first quarter. Oppenheimer Asset Management Inc. now owns 8,694 shares of the company’s stock valued at $511,000 after buying an additional 664 shares during the last quarter. Finally, ProShare Advisors LLC grew its holdings in shares of Apellis Pharmaceuticals by 11.6% during the first quarter. ProShare Advisors LLC now owns 8,452 shares of the company’s stock valued at $497,000 after buying an additional 881 shares during the last quarter. 96.29% of the stock is owned by institutional investors.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).